AnaptysBio (NASDAQ:ANAB) Receives “Outperform” Rating from Wedbush

Wedbush restated their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note issued to investors on Wednesday morning,RTT News reports. The firm currently has a $40.00 price objective on the biotechnology company’s stock.

Several other research firms have also recently commented on ANAB. BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Wolfe Research initiated coverage on AnaptysBio in a report on Tuesday, February 4th. They set an “outperform” rating and a $25.00 price objective for the company. Guggenheim lowered their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. JPMorgan Chase & Co. dropped their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Finally, Wells Fargo & Company decreased their price target on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and an average price target of $40.08.

AnaptysBio Price Performance

ANAB opened at $16.15 on Wednesday. The firm has a market capitalization of $491.44 million and a P/E ratio of -2.66. AnaptysBio has a one year low of $12.21 and a one year high of $41.31. The company has a fifty day moving average price of $16.06 and a 200-day moving average price of $25.98.

Insider Buying and Selling

In related news, Director Ecor1 Capital, Llc bought 65,184 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was bought at an average cost of $12.92 per share, for a total transaction of $842,177.28. Following the acquisition, the director now directly owns 7,860,180 shares of the company’s stock, valued at $101,553,525.60. The trade was a 0.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 33.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On AnaptysBio

A number of large investors have recently bought and sold shares of ANAB. KLP Kapitalforvaltning AS bought a new position in shares of AnaptysBio in the fourth quarter worth approximately $40,000. Values First Advisors Inc. purchased a new stake in AnaptysBio during the 3rd quarter valued at $49,000. nVerses Capital LLC grew its holdings in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 1,400 shares during the last quarter. AlphaQuest LLC increased its position in shares of AnaptysBio by 1,891.5% in the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 4,237 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of AnaptysBio by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 644 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.